- U.K. cost gatekeeper NICE wants more information from Sanofi (NASDAQ:SNY) on the MS treatment Lemtrada.
- The company will need to submit the supplementary information by January 9.
- SNY could certainly do without any further setbacks for the drug after FDA briefing documents raised questions about the treatment's safety profile last month.
- Lemtrada CVRs: ((GCVRZ))